This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log in
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 15;6(1):82.
doi: 10.1038/s41541-021-00338-z.

The future of Japanese encephalitis vaccination: expert recommendations for achieving and maintaining optimal JE control

Collaborators, Affiliations

The future of Japanese encephalitis vaccination: expert recommendations for achieving and maintaining optimal JE control

Kirsten S Vannice et al. NPJ Vaccines. .

Abstract

Vaccines against Japanese encephalitis (JE) have been available for decades. Currently, most JE-endemic countries have vaccination programs for their at-risk populations. Even so, JE remains the leading recognized cause of viral encephalitis in Asia. In 2018, the U.S. Centers for Disease Control and Prevention and PATH co-convened a group of independent experts to review JE prevention and control successes, identify remaining scientific and operational issues that need to be addressed, discuss opportunities to further strengthen JE vaccination programs, and identify strategies and solutions to ensure sustainability of JE control during the next decade. This paper summarizes the key discussion points and recommendations to sustain and expand JE control.

PubMed Disclaimer

Conflict of interest statement

No conflicts of interest: G.W.L., J.M.H., J.H., S.H., L.M.S., K.V., A.A.M. T.S. is supported by the National Institute for Health Research (NIHR) Health Protection Research Unit in Emerging and Zoonotic Infections (Grant No. IS-HPU-1112-10117), NIHR Global Health Research Group on Brain Infections (No. 17/63/110), and the European Union’s Horizon 2020 research and innovation program ZikaPLAN (Preparedness Latin America Network), grant agreement No. 734584. A.D.T.B. is Editor in Chief of npj Vaccines.

Figures

Fig. 1
Fig. 1. Areas with risk of Japanese encephalitis (JE) transmission and JE vaccine introduction relative to the WHO JE vaccine prequalification year (2013).
While some countries have implemented national public health JE vaccine programs, others may have only introduced in high risk areas.

References

    1. Halstead, S. B., Hills, S. L. & Dubischar, K. in Plotkin’s Vaccines (Seventh Edition) (Eds. Plotkin, S. A. et al.) 511–548.e12 (Elsevier, 2018).
    1. Heffelfinger JD, et al. Japanese encephalitis surveillance and immunization — Asia and Western Pacific Regions, 2016. Mmwr. Morbidity Mortal. Wkly. Rep. 2017;66:579–583. doi: 10.15585/mmwr.mm6622a3. - DOI - PMC - PubMed
    1. World Health Organization. Weekly epidemiological record Relevé épidémiologique hebdomadaire. WHO Weekly epidemiological record90, 69–87 (2015).
    1. Schneider RJ, Firestone MH, Edelman R, Chieowanich P, Pornpibul R. Clinical sequelae after japanese encephalitis: a one year follow-up study in Thailand. Southeast Asian J. Trop. Med Public Health. 1974;5:560–568. - PubMed
    1. Kamala CS, Rao MV, George S, Prasanna NY. Japanese encephalitis in children in Bellary Karnataka. Indian Pediatr. 1989;26:445–452. - PubMed
Full text links
Nature Publishing Group full text link Nature Publishing Group Free PMC article
Cite

AltStyle によって変換されたページ (->オリジナル) /